Zhejiang Guobang Pharmaceutical Co., Ltd.

Zhejiang Guobang Pharmaceutical Co., Ltd. was established in October 2000 and is a core enterprise under Guobang Pharmaceutical & Chemical Group. It is located in Shangyu District, Shaoxing City, Zhejiang Province, between the provincial capital Hangzhou and the coastal city Ningbo, in the hinterland of the Yangtze River Delta Economic Circle. Two cross-sea bridges provide direct access to Shanghai, and airports, high-speed rail, expressways, national highways, canals and ports are all available, making transportation very convenient.
The company is a key high-tech enterprise of the National Torch Program and has passed National Level II Safety Standardization, ISO 9001:2008 Quality Management System and ISO14001 Environmental Management System certifications. All products have passed national pharmaceutical and veterinary drug GMP certification; its leading products have passed EU GMP, US FDA, Japan PMDA, Brazil ANVISA, Korea KFDA and other certifications. It has a postdoctoral research workstation, a provincial pharmaceutical research institute and a provincial enterprise technology center.
The company covers an area of 450 mu, with total assets of 1.5 billion yuan and sales of over 1.6 billion yuan in 2015. It currently has more than 1,300 employees, of whom over 32% have college degrees or above, mainly from renowned universities such as Tsinghua University, Zhejiang University, Tianjin University, Wuhan University, Huazhong University of Science and Technology, Dalian University of Technology and China Pharmaceutical University, playing important roles in the company's research, production, management, sales and other positions.
With pharmaceutical and chemical technology as its core, the company is mainly engaged in the research and development, production and operation of pharmaceutical APIs and veterinary drug APIs, and is a well-known domestic manufacturer of chemically synthesized pharmaceutical raw materials and veterinary drug raw materials. Its leading products are quinolone antibacterials, macrolide antibacterials, cephalosporin antibacterials and antitumor drugs, among which ciprofloxacin hydrochloride, enrofloxacin, azithromycin, clarithromycin, roxithromycin and other products are major global manufacturers, with production capacity and market share both reaching over 30% of domestic and international markets. Products are exported to 96 countries and regions, and the sales network covers all parts of the country as well as markets in the United States and European countries.
The company adheres to putting strivers first, upholds the philosophy of "cultivating people and building the nation, prospering business and strengthening the country" and the purpose of "sharing the beauty of science, nature and life", and will redouble its efforts to devote itself to the development of the pharmaceutical industry, shoulder the social responsibility of pharmaceutical enterprises, dedicate products to society, and continuously make new contributions to the health of the people.